Cheng-Long Xie

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2937022/publications.pdf

Version: 2024-02-01

933447 888059 18 440 10 17 citations g-index h-index papers 18 18 18 746 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Plasma long non-coding RNA BACE1 as a novel biomarker for diagnosis of Alzheimer disease. BMC Neurology, 2018, 18, 4.	1.8	99
2	Neuroprotective properties of curcumin in toxin-base animal models of Parkinson's disease: a systematic experiment literatures review. BMC Complementary and Alternative Medicine, 2017, 17, 412.	3.7	82
3	The efficacy and safety of coenzyme Q10 in Parkinson's disease: a meta-analysis of randomized controlled trials. Neurological Sciences, 2017, 38, 215-224.	1.9	76
4	Effects of neurostimulation for advanced Parkinson's disease patients on motor symptoms: A multiple-treatments meta-analysas of randomized controlled trials. Scientific Reports, 2016, 6, 25285.	3.3	34
5	Neuroprotective effects of curcumin via autophagy induction in 6-hydroxydopamine Parkinson's models. Neurochemistry International, 2022, 155, 105297.	3.8	18
6	Effects of mGluR5 Antagonists on Parkinson's Patients With L-Dopa-Induced Dyskinesia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Frontiers in Aging Neuroscience, 2018, 10, 262.	3.4	17
7	NAD+ in Alzheimer's Disease: Molecular Mechanisms and Systematic Therapeutic Evidence Obtained in vivo. Frontiers in Cell and Developmental Biology, 2021, 9, 668491.	3.7	17
8	Modulation of CaMKIIa-GluN2B interaction in levodopa-induced dyskinesia in 6-OHDA-lesioned Parkinson's rats. Biomedicine and Pharmacotherapy, 2018, 107, 769-776.	5.6	14
9	Lipoic acid alleviates L‑DOPA‑induced dyskinesia in 6‑OHDA parkinsonian rats via anti‑oxidative stress. Molecular Medicine Reports, 2017, 17, 1118-1124.	2.4	13
10	Current Experimental Studies of Gene Therapy in Parkinson's Disease. Frontiers in Aging Neuroscience, 2017, 9, 126.	3 . 4	12
11	β-arrestin2 alleviates L-dopa–induced dyskinesia via lower D1R activity in Parkinson's rats. Aging, 2019, 11, 12315-12327.	3.1	10
12	A Meta-Analysis of Adenosine A2A Receptor Antagonists on Levodopa-Induced Dyskinesia In Vivo. Frontiers in Neurology, 2017, 8, 702.	2.4	9
13	Delineating the Role of Mitophagy Inducers for Alzheimer Disease Patients. , 2021, 12, 852.		9
14	Striatal overexpression of \hat{l}^2 -arrestin2 counteracts L-dopa-induced dyskinesia in 6-hydroxydopamine lesioned Parkinson's disease rats. Neurochemistry International, 2019, 131, 104543.	3.8	8
15	Levodopa/Benserazide PLGA Microsphere Prevents L-Dopa–Induced Dyskinesia via Lower β-Arrestin2 in 6-Hydroxydopamine Parkinson's Rats. Frontiers in Pharmacology, 2019, 10, 660.	3 . 5	7
16	Neuroprotective effects of N-acetyl cysteine on primary hippocampus neurons against hydrogen peroxide-induced injury are mediated via inhibition of mitogen-activated protein kinases signal transduction and antioxidative action. Molecular Medicine Reports, 2018, 17, 6647-6654.	2.4	6
17	An Overview of Meta-Analyses of Endovascular Bridging Therapies for Acute Ischemic Stroke. BioMed Research International, 2018, 2018, 1-12.	1.9	6
18	The Advantages of Levodopa-Carbidopa Intestinal Gel for Patients with Advanced Parkinson's Disease: A Systematic Review. Drug Design, Development and Therapy, 2020, Volume 14, 845-854.	4.3	3